| Pair Name | Luteolin, Bortezomib | ||
| Phytochemical Name | Luteolin (PubChem CID: 5280445 ) | ||
| Anticancer drug Name | Bortezomib (PubChem CID: 387447 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Luteolin, Bortezomib | |||
| Disease Info | [ICD-11: 2A83.1] | Multiple myeloma | Investigative | |
| Gene Regulation | Down-regulation | Expression | ALDH1A1 | hsa216 |
| Down-regulation | Expression | TGFBR1 | hsa7046 | |
| Down-regulation | Phosphorylation | SMAD2 | hsa4087 | |
| In Vitro Model | ANBL-6 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_5425 |
| ARP-1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_D523 | |
| KMS-11 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_2989 | |
| MM1.S | Plasma cell myeloma | Homo sapiens (Human) | CVCL_8792 | |
| RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 | |
| In Vivo Model | Female BALB/c nude mice were subcutaneously inoculated in the flank with 5×10⁶ luciferase-labeled ARP1 cells in 200 μL of PBS. NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt (NCG) mice were subcutaneously inoculated in the flank with 1×107 luciferase-labeled ARP1-BR cells in 200 μL of PBS. | |||
| Result | Our findings suggested that LUT is a promising agent that manifests MMSCs to overcome BTZ resistance, alone or in combination with BTZ, and thus, is a potential therapeutic drug for the treatment of MM. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma. Cancer Lett. 2023 Feb 1;554:216019. doi: 10.1016/j.canlet.2022.216019. | Click |
